Methods: Isoelectric focusing on the PhastSystem TM followed by immunofixation, silver staining, and densitometry was used to validate the initial transferrin isoform fractionation step on anion-exchange microcolumns involved in the ChronAlcoI.D.
CDT, regardless of which method is used. Detailed information on the reliability of the initial transferrin fractionation is needed for each CDT analytical method. This is true not only for routine analysis in accordance with good laboratory practice, but also when comparing values and diagnostic specificities and sensitivities of CDT obtained in different clinical settings with different CDT analytical methods (13) (14) (15) . Recently, a new CDT test, ChronAlcoI.D. TM , was developed by Sangui BioTech, Inc. (Santa Ana, CA), formerly distributed by DPC/Biermann (Bad Nauheim, Germany) and currently by Biodiagnostics GmbH (Kiel, Germany). According to the test instructions, this assay measures asialo-, monosialo-, and disialoFe 2 -transferrin and thus uses the common CDT definition given by Stibler (16 ) . Therefore, this test might be an interesting replacement for the widely used CDTect enzyme immunoassay, the production of which was terminated in January 1999. Despite its increased use for routine determination of CDT (17 ) , information about the reliability of the CDT and non-CDT fractionation step in the ChronAlcoI.D. assay is lacking at present. In continuation of our investigation of the CDTect assay (13 ), we assessed this part of the ChronAlcoI.D. assay.
The aim of our study was to assess which transferrin isoforms are measured as CDT by the ChronAlcoI.D. assay. The following points, which are crucial for the specificity of the initial CDT and non-CDT transferrin isoform fractionation step, were investigated: (a) the efficiency of the in vitro transferrin iron-saturation step (which is used to establish a unique transferrin iron load by formation of Fe 2 -transferrins and elimination of Fe 1 -and Fe 0 -transferrins); (b) the transferrin iron load stability during passage over the anion-exchange columns to prevent coelution of non-CDT and CDT transferrins with differing iron and sialic acid content but identical pI values; (c) the efficiency of the initial CDT and non-CDT transferrin fractionation step on the anion-exchange microcolumns; (d) the reproducibility of the anion-exchange microcolumn separation; and (e) possible effects of genetic transferrin D variants on the ChronAlcoI.D. assay results. Knowing which transferrin isoforms, and to what extent they are measured as CDT by the CDT analysis tests currently available, will undoubtedly be helpful for further studies on the pathomechanisms of CDT increases and for the diagnostic efficiency of CDT as the most specific marker of chronic alcohol abuse at present.
Materials and Methods materials
All chemicals used for IEF and silver staining were of analytical grade and were obtained from Merck, except Pharmalytes 5-6 (Pharmacia/LKB), and acrylamide and bisacrylamide (Serva). Polyclonal rabbit IgG antibodies to human transferrin were from Dako. The ChronAlcoI.D. assay and the CDT control set (both from Sangui BioTech) were provided by DPC/Biermann.
serum samples
All procedures were performed in accordance with the Helsinki Declaration of 1975, as revised in 1996.
Only surplus serum sample volumes from routine investigations were used. Blood was drawn after overnight fasting into sterile gel tubes (Sarstedt). The gel barrier consisted of a polymerized acrylic resin that does not affect the serum CDT concentration (18 ) . After clotting at room temperature for 30 min, the blood samples were centrifuged at 2000g for 10 min at 4°C. Serum was removed immediately with disposable pipettes (to avoid contamination with microorganisms); aliquots were transferred into sterile, leak-proof plastic containers (Micro Tubes with screw cap; Sarstedt) and stored at Ϫ22°C until the day of analysis.
ChronAlcoI.D. assay
Serum CDT concentrations and the CDT/transferrin ratios were determined by the ChronAlcoI.D. assay in accordance with the instructions of the manufacturer. The test comprises the following steps:
In vitro transferrin iron saturation. Serum or control sample (100 L) and ferric saturation reagent (500 L) are mixed and incubated for 5-10 min at room temperature.
Anion-exchange microcolumn separation of CDT-and non-CDT-transferrins. The Fe 3ϩ
-saturated serum or control sample (500 L) is pipetted directly onto the top of the filter of the microcolumn. The sample drains until the top filter appears dry, and the effluent (load step) is discarded (non-CDT transferrins and CDT transferrins adsorb to the anion exchanger). The column is rinsed with 1.5 mL of elution buffer, and the effluent (rinse step) is discarded. An additional volume of 2.5 mL of elution buffer is pipetted onto the column filter, the buffer drains until the filter appears dry, and the eluate is collected in appropriately labeled test tubes (CDT transferrins are eluted).
Preparation of the total transferrin solution. The total transferrin solution is prepared while microcolumn separation is taking place. The Fe 3ϩ -saturated serum or control sample (20 L) is mixed with 800 L of elution buffer. This sample is used in the following turbidimetric immunoassay for determination of the total serum transferrin concentration.
Quantification of CDT and total transferrin by a microtiterplate turbidimetric immunoassay. Calibrators, microcolumn eluates, and total transferrin dilution samples (200 L of each) are pipetted directly into the bottom of each well, and atypical absorbance (background) is read at 405 nm (Dynatec MR 5000 reader; Dynex Technologies). Transferrin antibody solution (100 L) is then added to each well. After gentle agitation for 15 min at room temperature, the absorbance is read at 405 nm. The analysis data were evaluated with Dynex Revelation 3.2 software (Dynex Technologies). The results were reported as CDT/ transferrin ratios as well as CDT concentrations.
Quality control for the whole ChronAlcoI.D. assay was in accordance with the guidelines of the German Federal Medical Association. Within each assay, serum pool aliquots with CDT values near the cutoff of 2.5-2.7% for women and men (17 ) , and two control samples with normal and increased CDT ratios (CDT control set; DPC/ Biermann) were used for internal quality control. The control samples were placed at the beginning and the end of each set of samples. Control and serum samples were analyzed in duplicate. The laboratory regularly participates in external quality-control programs.
ief, immunofixation, and silver staining
The efficiency of the in vitro iron-saturation step, the transferrin iron load stability during passage through the microcolumns, the efficiency and reproducibility of the fractionation of CDT and non-CDT-transferrins, and the possible effects of transferrin D variants were assessed by IEF analysis of the transferrin isoform patterns in the corresponding sample aliquots after each intermediate step of the ChronAlcoI.D. CDT and non-CDT fractionation procedure. We investigated (a) the serum samples after Fe 3ϩ -transferrin saturation (Fig. 1a , lanes A, and Fig.  3 ); (b) the column effluents after application of the irontreated serum samples to the top of the anion-exchange microcolumns; (c) the column effluents after the columns were rinsed with 1.5 mL of elution buffer (Fig. 1a, lanes B) ; (d) the column eluates after the addition of 2.5 mL of elution buffer to the column (this eluate usually is used for quantifying CDT in the final turbidimetric immunoassay; Fig. 1a , lanes C; Fig. 2 , lane 13; Figs. 3 and 4); and (e) additional 2 mol/L NaCl eluates that were used for recovery studies (usually not part of the original ChronAlcoI.D. test; Fig. 1a, lanes D) .
Because of the limited capacity of the IEF system, it was impossible to analyze all samples immediately after the original ChronAlcoI.D. step. Thus, serum samples and column effluents and eluates were frozen immediately and stored at Ϫ22°C until analysis (usually within 2 weeks). This sample storage (which is not part of the ChronAlcoI.D. assay, but which was part of our experimental setup) caused a partial loss of transferrin iron in the effluents and eluates, probably because of the ionic strength of the buffers used. To these samples, additional amounts of Fe 3ϩ were added, according to Hackler et al. (8 ) . Identical IEF transferrin patterns were obtained when we analyzed fresh samples and the same samples after freezing and additional Fe 3ϩ treatment in parallel. This demonstrates that our procedure is appropriate for readjusting the original complete transferrin iron load in thawed column effluents and eluates.
IEF. IEF was performed on the PhastSystem TM , followed by immunofixation and silver staining as described by Hackler et al. (8 ) with the modifications described by Arndt et al. (19 ) . In short, polyacrylamide gels, pH 5-6 (43 ϫ 50 ϫ 0.45 mm; total acrylamide content, 5%; cross-linker content, 3%; Pharmalyte 5-6 ® diluted 1:16, by volume), adhered to a plastic support film (GelBond TM PAG film; Biozym-Diagnostik), were prepared in house and prefocused for 75 V-h. Using the Sample Applicator TM 8/1 (Pharmacia/LKB), we applied eight samples (1 L of each sample). The sample applicator was inserted into the most cathodic position of the sample applicator arm. Sample application was performed for 15 V-h, and the separation was performed for 200 V-h.
Immunofixation. Immunofixation was done immediately after the IEF (20 ) . The gels were covered with 175 L of polyclonal IgG antibodies to transferrin (50 L of antibody diluted in 150 L of 150 mmol/L NaCl) and incubated at room temperature in a moist chamber for 40 min. Unprecipitated (non-transferrin) proteins were removed by washing the gels with 150 mmol/L NaCl overnight with vigorous agitation.
Silver staining. Silver staining was carried out in the PhastSystem Development Unit TM according to Hackler and Kleine (20 ) with the following modification: The staining reaction was stopped by incubating the gel in 50 mmol/L EDTA (instead of 50 mL/L acetic acid). The gels were washed in deionized water for 2 h, dried in air, and kept for documentation. Transferrin bands were identified by parallel analysis of a cerebrospinal fluid (CSF) sample in each gel, showing (physiologically) asialo-to hexasialo-Fe 2 -transferrin isoforms.
Densitometry. Densitometry was performed on a Preference densitometer (Sebia).
In adjusting the IEF sensitivity for detection of the CDT-transferrins, an overload of the tetrasialo-Fe 2 -transferrin fraction was accepted. Thus, the intensity (Fig. 1a) and peak height or peak area (Fig. 1b) of this tetrasialoFe 2 -transferrin fraction did not correlate with the transferrin content. In contrast to tetrasialo-Fe 2 -transferrin, asialo-, mono-, di-, and trisialo-Fe 2 -transferrin fractions were not overloaded. Thus, the peak heights or areas of these fractions could be used for determination of the percentage of the trisialo-Fe 2 -transferrin contamination from total CDT.
other assays
To achieve comparable transferrin band and peak intensities between lanes A (serum) and D (2 mol/L NaCl eluate) of Fig. 1 , the samples were diluted to a uniform total transferrin concentration of 8 mg/L. The total transferrin was determined with a Turbitimer and Turbiquant 
Results
We used IEF to evaluate the CDT and non-CDT transferrin fractionation step involved in determination of CDT by the ChronAlcoI.D. assay. A total of 170 column eluates were analyzed. Of these, 62 eluates (Fig. 1a , lanes C) were investigated together with the corresponding Fe 3ϩ -treated serum samples, and 36 were investigated together with the corresponding serum samples (Fig. 1a, lanes A) , column effluents (rinse step; Fig. 1a , lanes B), and 2 mol/L NaCl eluates (Fig. 1a, lanes D) ; for the nomenclature, see Materials and Methods. As the main result of our study, we found only CDT transferrin isoforms (asialo-, monosialo-, and disialo-Fe 2 -transferrin) in the ChronAlcoI.D. microcolumn eluates, except for quantitatively unimportant traces (Ͻ5% of total CDT) of trisialo-Fe 2 -transferrin. In testing the different points discussed earlier, we obtained the following results.
in vitro transferrin iron saturation
When in vitro transferrin iron saturation is complete, only transferrin iron load stability during passage over the anion-exchange microcolumn Transferrin iron loss, and thus reformation of Fe 0 -and Fe 1 -transferrins, can occur under nonoptimal pH conditions during the analytical process (8 ) . This loss can cause distinct overdetermination of CDT because of coelution of transferrin isoforms with differing sialic acid and iron content but the same pI (8 ) . Thus, we checked the 2.5-mL eluates (which are used in the final CDT quantification step of the ChronAlcoI.D. assay) for the presence of Fe 0 -and Fe 1 -transferrins immediately after the elution step and after additional amounts of Fe 3ϩ were added according to the method of Hackler et al. (8 ) . Altogether, 170 column eluates (which are used in the final turbidimetric immunoassay involved in the ChronAlcoI.D. test) were assessed (lanes C of Fig. 1a ; lane 13 of Fig. 2 ; lanes "Eluate" of Fig. 3; and lanes 1-7 of Fig. 4) . When fresh effluents and eluates (as obtained by the original ChronAlcoI.D. procedure) were analyzed, Fe 0 -and Fe 1 -transferrins were not detected. The added Fe 3ϩ did not affect the transferrin band patterns, which demonstrates a complete and stable transferrin iron load during passage over the microcolumn. Examination of the column effluents and eluates only a few hours after the elution step showed a small transferrin iron loss (weak bands of Fe 0 -and Fe 1 -transferrins). The loss was marked after storage of the eluates for 3 months at Ϫ22°C. After we added Fe 3ϩ to these samples (to readjust the original transferrin iron load), we could no longer detect bands of Fe 0 -and Fe 1 -transferrin or of more highly sialylated non-CDT transferrins by IEF. This demonstrates that the transferrin iron loss occurred during the sample storage, but not during the CDT and non-CDT fractionation on the anionexchange microcolumns. To test this point further, we determined the CDT/transferrin ratio and the CDT concentration from column eluates of seven serum samples with normal and increased CDT after storage for 1, 2, 3, and 6 days at 4 -8°C without adding further amounts of Fe 3ϩ . The corresponding CVs were between 3.2% and 10%, which is close to the imprecision of the ChronAlcoI.D. assay reported by Arndt et al. (17 ) . We conclude that the transferrin iron saturation in accordance with the test instructions of the ChronAlcoI.D. assay was complete and stable during the CDT and non-CDT transferrin fractionation procedure. It permits reliable elimination of Fe 0 -and Fe 1 -transferrins and thus a uniform Fe 2 -transferrin iron load in serum samples. The column eluates can be stored at 4 -8°C overnight without the risk of false CDT results in the final ChronAlcoI.D. turbidimetric immunoassay.
cdt and non-cdt transferrin fractionation
This part of the assay consists of three intermediate steps: application of the Fe 3ϩ -treated serum to the microcolumn, rinsing the column, and eluting the CDT transferrins. The specificity of the microcolumn separation was tested by IEF of the transferrin isoforms occurring in these matrices. We analyzed 6 column effluents from the loading step, 36 column effluents from the washing step, and 170 column eluates. We did not detect transferrins in the column effluent from the loading step, confirming that there was complete adsorption of all transferrin isoforms to the anion exchanger (not shown). Distinct amounts of asialoFe 2 -transferrin appeared in all column effluents during the wash step, regardless of whether normal or increased amounts of CDT appeared in the serum sample (Fig. 1a,  lanes B; Fig. 2, lanes 5 and 6) , revealing that this CDT transferrin was partially lost when the microcolumns were rinsed. The column eluates (which are used for the final CDT quantification) contained asialo-, mono-, and disialo-Fe 2 -transferrin, which collectively are referred to as CDT (16 ) , and traces of trisialo-Fe 2 -transferrin (Fig. 1a,  lanes C; Fig. 2, lane 13; Fig. 3, lane "Eluate"; Fig. 4 ). The recovery of CDT was tested by eluting the microcolumns with 1 mL of 2 mol/L NaCl (the optimal volume for complete elution of all transferrin isoforms from the anion exchanger was assessed by fractionated elution in 500-L steps). The 2 mol/L NaCl eluates contained mainly more highly sialylated, non-CDT transferrins (tri-, tetra-, penta-, and hexasialo-Fe 2 -transferrin) but also disialo-Fe 2 -transferrin. The latter finding reflects a partial retention of this CDT transferrin by the anion exchanger. Altogether, we found a partial loss of asialo-Fe 2 -transferrin in the column rinse step and a partial loss of disialo-Fe 2 -transferrin on the anion exchanger. This incomplete recovery of CDT was observed for serum samples with normal as well as with increased CDT concentration.
We tested by fractionated rinsing and fractionated elution whether the elution buffer volumes for rinsing the microcolumns and eluting the CDT transferrins, and thus the CDT recovery, could be optimized (Fig. 2) . As shown in Fig. 2 , an elution buffer volume of 1.0 mL (instead of 1.5 mL) would be sufficient for rinsing the column. With this volume, asialo-Fe 2 -transferrin would be completely retained on the anion exchanger (Fig. 2, lanes 1-4) . Rinse volumes Ͼ1.0 mL, e.g., 1.5 mL in accordance with the test instructions, cause a partial loss of asialo-Fe 2 -transferrin (Fig. 2, lanes 5 and 6) . Increasing the buffer volume for eluting the CDT transferrins from 2.5 mL (original volume) to 3.0 mL (Fig. 2, lane 12) would improve the recovery of disialo-Fe 2 -transferrin, but at the same time it would exacerbate the coelution of trisialo-Fe 2 -transferrin. Reducing the elution buffer volume from 2.5 mL to 2.0 mL allows almost complete retention of trisialo-Fe 2 -transferrin (Fig. 2, lane 10) , but it also allows higher loss of disialo-Fe 2 -transferrin on the anion exchanger.
To assess the extent of CDT loss by the ChronAlcoI.D. transferrin isoform fractionation step, we diluted serum samples and the corresponding microcolumn eluates (which are used in the final turbidimetric immunoassay) to obtain similar peak heights for disialo-Fe 2 -transferrin (Fig. 3) . Taking into account the different dilution factors, the CDT loss was estimated to be ϳ30%. We also used these samples to test whether the CDT transferrin patterns in the eluate are representative of those in the iron-treated serum samples. Comparing the serum disialo-Fe 2 -transferrin/asialo-Fe 2 -transferrin peak height ratios with those of the corresponding ChronAlcoI.D. eluate (Fig. 3) showed that the transferrin isoform patterns in the ChronAlcoI.D. column eluates are representative of the transferrin isoform pattern in the serum sample. The almost identical disialo-Fe 2 -transferrin/asialo-Fe 2 -transferrin peak height ratios in serum (3.2) and eluate (3.4) indicate a proportionally similar loss of asialo-Fe 2 -transferrin (during column rinsing) and disialo-Fe 2 -transferrin (on the anion exchanger). Thus, the disialo-Fe 2 -transferrin/asialoFe 2 -transferrin peak height ratios did not change from Ͼ1 (serum) to Ͻ1 (eluate) as described for the CDTect assays (13 ) . Identical results were obtained for serum samples with normal and increased CDT concentration (Figs. 1  and 3 ). An important fact is that increased CDT fractions in serum were always reflected in the corresponding microcolumn eluates. This is another indication that the ChronAlcoI.D. microcolumn eluates are representative of the serum sample. Altogether, the original ChronAlcoI.D. CDT and non-CDT transferrin fractionation procedure Fig. 2 . Efficiency of the elution buffer volumes for rinsing the anion-exchange microcolumns after application of the serum samples to the column and for eluting the CDT-transferrins from the anion exchanger.
Lanes 1-6, transferrin isoform patterns after fractionated rinsing in six steps (250 L of elution buffer in each step) instead of application of the original 1500-L volume in one step to the column. Lanes 7-11, transferrin isoform patterns after fractionated elution in five steps (500 L of elution buffer in each step) instead of application of the original 2.5-mL volume in one step. Lane 12, IEF transferrin band pattern after the accumulated elution volume was increased to 3.0 mL. Lane 13, transferrin pattern in the original ChronAlcoI.D. eluate, which was obtained in accordance with the test instructions. The original buffer volume for rinsing the column causes a partial loss of asialo-Fe 2 -transferrin. Increasing the buffer volume for the CDT-transferrin elution step yields a distinct coelution of trisialo-Fe 2 -transferrin. Similar results were obtained for serum samples with normal CDT/transferrin ratios and normal CDT concentrations. The CDT/transferrin ratio of the serum shown here was 9.0%, and the CDT concentration was 369 mg/L. Because of the different effective elution volumes (250 L for each of lanes 1-6; 500 L for each of lanes 7-12), the intensities of the transferrin isoform fractions in lanes 1-12 are not comparable with those in lane 13 (effective elution volume, 2500 L). Numbers to the left of lane CSF indicate number of sialic acid residues. Tf, transferrin.
yields reliable separation and thus specific determination of CDT in the final turbidimetric immunoassay. The elution buffer volume of 2.5 mL seems to be a good compromise between maximum analytical specificity (exclusion of more highly sialylated non-CDT transferrins, e.g., trisialotransferrin and, most important, tetrasialotransferrin) on the one hand and maximum recovery of CDT on the other hand.
reproducibility of the microcolumn performance
The within-run reproducibility of the whole CDT and non-CDT transferrin fractionation step was tested by processing seven aliquots of the same serum sample with increased CDT using seven different columns in one analytical run. When we calculated the means, SDs, and CVs of the peak height ratios of disialo-Fe 2 -transferrin/ monosialo-Fe 2 -transferrin, disialo-Fe 2 -transferrin/asialoFe 2 -transferrin, and monosialo-Fe 2 -transferrin/asialo-Fe 2 -transferrin for each serum sample, we obtained imprecision values (CVs) of 5%, 9%, and 10%, respectively (Fig.  4) , which were comparable to the intraassay imprecision (9%) of the whole ChronAlcoI.D. (17 ) . (Fig. 1a) reflect the chronic alcohol abuse of this patient.
The IEF transferrin band pattern in the column effluent (rinse step) is shown in lane B of the alcoholic (Tf C1D) pattern in Fig. 1a . The two bands represent asialo-Fe 2 -transferrin D (most cathodic and more intense band) and asialo-Fe 2 -transferrin C1 (more anodic band). Lane B shows that larger amounts of the asialo-Fe 2 -transferrin D in comparison with asialo-Fe 2 -transferrin C1 were lost when the column was rinsed. Lane C of the alcoholic (Tf C1D) pattern in Fig. 1a shows the transferrin isoform pattern in the column eluate (CDT elution step). The band pattern is complex, with two distinct bands corresponding to disialo-Fe 2 -transferrin C1 (more anodic band) and disialo-Fe 2 -transferrin D (more cathodic band). The first Serum and eluate were diluted to obtain similar peak intensities for disialo-Fe 2 -transferrin. In comparing the different dilution factors, the CDT loss on the anion exchanger was estimated to be ϳ30%. Almost identical peak height ratios of disialo-to asialo-Fe 2 -transferrin indicate that the losses of asialo-Fe 2 -transferrin (in the column rinse step) and of disialo- 
Discussion
The specific chromatographic or electrophoretic separation of non-CDT and CDT transferrins is complicated by the identical isoelectric points of transferrin isoforms with differing iron and sialic acid content, e.g., disialo-Fe 2 -transferrin as a major CDT transferrin and tetrasialo-Fe 1 -transferrin as the main non-CDT transferrin (8, (21) (22) (23) . In establishing a uniform transferrin iron load, the number of potential serum transferrin isoforms is reduced from 36 to 9 for homozygous and from 72 to 18 for heterozygous transferrin phenotypes (21 ) . Minimal isoelectric point differences of 0.1 pH units for transferrins with a uniform iron load but different sialic acid content, e.g., disialo-and trisialo-Fe 2 -transferrin (21 ), further complicate CDT analysis. Therefore, a complete and stable transferrin iron load and reliable CDT and non-CDT fractionation are prereq- uisites for correct determination of CDT (8, 13 ) . We investigated the initial CDT and non-CDT transferrin fractionation step used in the ChronAlcoI.D. assay. The data obtained in this study show reliable separation of CDT and non-CDT transferrins on the anion-exchange microcolumns and a high precision in the microcolumn performance. Whether trisialo-Fe 2 -transferrin should be (partially) incorporated in CDT has been discussed previously (13, 24 (4, 24, 26 -30 ) . Indeed, increased total transferrin concentrations, e.g., because of pregnancy or irondeficiency anemia, can potentially cause increased serum CDT concentrations and thus false positives with respect to alcohol abuse. Under these conditions, the CDT/ transferrin ratio may be more specific for detection of chronic alcohol abuse than the CDT concentration. However, under the condition of reduced total transferrin concentrations, e.g., because of hemochromatosis, false positives are likely when the CDT/transferrin ratio is used instead of the CDT concentration. Recently, Helander (31 ) reported an overall similar diagnostic performance of absolute and relative CDT values. In our experience based on several thousand CDT analyses, both CDT and the CDT/transferrin ratio should be analyzed, and the total transferrin concentration should be taken into account (17 ) . In doing so, false positives attributable to abnormal total transferrin concentrations can be reduced as far as possible. It would be interesting to reevaluate the data published in the various clinical reports on CDT from this point of view.
In conclusion, with correct use, the initial CDT and non-CDT fractionation step involved in determination of CDT by the ChronAlcoI.D. assay is an efficient procedure for the elimination of non-CDT transferrins from the serum sample before CDT quantification in the final turbidimetric immunoassay. A standardization of CDT analysis is urgently needed.
